VirtualScopics Inc

VirtualScopics — Shareholder Meeting (August 2013)

54 slides from VirtualScopics's shareholder meeting presentation, Aug 13, 2013

  1. Slide 1: Annual Stockholders' Meeting August 13, 2013

    Annual Stockholders’ Meeting August 13, 2013

  2. Slide 2: Meeting Overview

    VirtualScopics All Rights Reserved 2 Meeting Overview Introductions and Opening Remarks • Robert Klimasewski, Chairman Proxy Summons Business Overview • Jeff Markin/Molly Henderson Question and Answer Proxy Tally and Results • Robert Klimasewski

  3. Slide 3: 2013 Proxy Summons

    VirtualScopics All Rights Reserved 3 2013 Proxy Summons Election of Board of Directors for 2013/2014 Ratify the appointment of Marcum LLP as independent financial statement auditors for the fiscal year ended December 31, 2013 To approve an amendment to our Certificate of Incorporation to effect a re

  4. Slide 4: Meeting Overview

    VirtualScopics All Rights Reserved 4 Meeting Overview Introductions and Opening Remarks • Robert Klimasewski, Chairman Proxy Summons Business Overview • Jeff Markin/Molly Henderson Question and Answer Proxy Tally and Results • Robert Klimasewski

  5. Slide 5: Forward-looking statements

    VirtualScopics All Rights Reserved 5 This presentation contains “forward - looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 . Such forward - looking statements involve known and unknown risks, uncertainties, and other factors, which may cause the actual

  6. Slide 6: Company & Business Overview

    Company & Business Overview Jeff Markin President and CEO Molly Henderson Chief Business & Financial Officer

  7. Slide 7: Business Meeting Agenda

    VirtualScopics All Rights Reserved 7 Business Meeting Agenda Business Review - Clinical Trial Business - Personalized Medicine Business Financial Review - Historical summary - Industry comparisons and multiples - 2013 outlook Financial Markets - Approach with NASDAQ - Stock Price - CFO Replacement Q

  8. Slide 8: Clinical Trials Business

    VirtualScopics All Rights Reserved 8 Clinical Trials Business Business Overview Q2 Results 2013 Business Imperatives

  9. Slide 9: Imperatives for Clinical Trials Business

    VirtualScopics All Rights Reserved 9 Imperatives for Clinical Trials Business • Address the overall slow down in new project awards • Increase the effectiveness/sales through the PPD channel • Deliver infrastructure and technology investments required to for Phase III studies Recap of 2012 Annual Me

  10. Slide 10: Imperatives for Clinical Trials Business: Recap of 2012 Annual Meeting

    VirtualScopics All Rights Reserved 10 Imperatives for Clinical Trials Business • Address the overall slow down in new project awards • Increase the effectiveness/sales of the PPD channel • Deliver infrastructure and technology investments required to deliver on Phase III studies Recap of 2012 Annual

  11. Slide 11: Company Mission

    VirtualScopics All Rights Reserved 11 Our mission is to improve the lives of those impacted by disease and disability Company Mission

  12. Slide 12: Business Focus

    VirtualScopics All Rights Reserved 12 Business Focus Drug Development • 13 Years in the industry • Strong reputation doing business with 12 of the top 15 global pharmaceutical and Biotech companies • Significant Assets • Leading technology and Scientific position • A model that is capable of generat

  13. Slide 13: Business Focus

    VirtualScopics All Rights Reserved 13 Business Focus Drug Development • 13 Years in the industry • Strong reputation doing business with 12 of the top 15 global pharmaceutical and Biotech companies • Significant Assets • Leading technology and Scientific position • A model that is capable of generat

  14. Slide 14: Clinical Trials Focus: Key Company Highlights

    VirtualScopics All Rights Reserved 14 Clinical Trials Focus VirtualScopics is a leading provider of quantitative imaging for clinical trials • Integrated solution delivered as a series of services. • Highly automated quantitative analysis vs. conventional qualitative radiologist driven analysis. • V

  15. Slide 15: Q2 and Year to Date Results

    Q2 and Year to Date Results GF VIRTUALSCOPICS

  16. Slide 16: Q2 Financial Highlights

    VirtualScopics All Rights Reserved 16 Q2 Financial Highlights • Revenue +14% • Gross Margin +20% • Adjusted EBITDA +$400K • Positively impacted due to large study in the quarter that will not be recurring • Rate of margin growth exceeds revenue growth signaling strong economies of scale • Significan

  17. Slide 17: New Study Awards Sales Performance

    VirtualScopics All Rights Reserved 17 0 2 4 6 8 10 12 14 16 18 2012 2013 Year to Date New Study Awards Sales Performance • New study awards +244% • PPD Represents 40% year to date awards • Includes 10 new clients for the company $Millions • A good trend off a weak 2012 • More work still needed to po

  18. Slide 18: Phase III Cancer Study

    VirtualScopics All Rights Reserved 18 Challenge – Compressed Time Frame • Analysis on critical path to regulatory submission • Approximately 10,000 scans to be evaluated • 6 week contract period Results • Completed 1 week early beating deadline by 20% • According to the client quality was “IMPRESSIV

  19. Slide 19: 3rd Generation Analysis System

    VirtualScopics All Rights Reserved 19 3 rd Generation Analysis System A week 4 timepoint showing tumor changes over time. The baseline timepoint shows the initial state of disease. Lesions can be identified using a semi - automated technique. A wide range of biomarkers are computed including volume

  20. Slide 20: Summary

    VirtualScopics All Rights Reserved 20 • Strong quarter financially • Significant rebound in new study awards • Prominent debut of our new 3 rd generation reading system with the early and very high quality delivery of a large PIII Oncology Study • Good progress • More work needed Summary

  21. Slide 21: 2013 Business Imperatives

    2013 Business Imperatives GF VIRTUALSCOPICS

  22. Slide 22: 2013 Imperatives Deliverables

    VirtualScopics All Rights Reserved 22 2013 Imperatives Deliverables Meet Financial Goals and Return to Growth Expand Expertise and Capability New Study Awards PPD Alliance

  23. Slide 23: Meet Financial Goals

    VirtualScopics All Rights Reserved 23 Revenue • 2013 largely in place with backlog and bookings to date • 2014 building with aggressive the sales efforts and resulting success • Getting back to growth our key focus Cost • Took cost action during the 2 nd quarter to better align our cost structure to

  24. Slide 24: New Study Awards

    VirtualScopics All Rights Reserved 24 • Turnaround actions to date largely tactical focusing on – Sales process – Client satisfaction – Operational excellence/continuous improvement • 2013 focus more strategic in nature(on top of holding the gains we have made to date) – Greater penetration/focus on

  25. Slide 25: PPD

    VirtualScopics All Rights Reserved 25 • Build upon recent successes – High client satisfaction – Case studies highlighting tangible benefits through implementation of the integrated solution – Strong partnership with PPD’s sales and operational teams – Implementation of the sales incentive plan for

  26. Slide 26: Expand Capabilities

    VirtualScopics All Rights Reserved 26 • Approximately 20% of new study awards in 2013 include capabilities we did not have 2 - 3 years ago • Plan to accelerate this via expansion of – Therapeutic area expertise and experience – Additional sales channels – Adjacent markets where our core capabilities

  27. Slide 27: Personalized Medicine

    Personalized Medicine GF VIRTUALSCOPICS

  28. Slide 28: Business Focus

    VirtualScopics All Rights Reserved 28 Business Focus Drug Development • 13 Years in the industry • Strong reputation doing business with 12 of the top 15 global pharmaceutical and Biotech companies • Significant Assets • Leading technology and Scientific position • A model that is capable of generat

  29. Slide 29: Business Focus

    VirtualScopics All Rights Reserved 29 Business Focus Drug Development • 13 Years in the industry • Strong reputation doing business with 12 of the top 15 global pharmaceutical and Biotech companies • Significant Assets • Leading technology and Scientific position • A model that is capable of generat

  30. Slide 30: Market Opportunity – Clinical

    VirtualScopics All Rights Reserved 30 • Emphasis on controlling the increasing cost of healthcare • Products and services that assist in patient stratification and rapid determination of efficacy or futility for expensive therapies are critical • Offer significant financial returns for organizations

  31. Slide 31: Benefits of Quantitative Imaging

    VirtualScopics All Rights Reserved 31 Precise measurements Repeatable results Enabling early diagnosis and drug mechanism of action confirmation Benefits of Quantitative Imaging Yet, the majority of assessments done today are still qualitative Significant opportunity to expand the imaging market by

  32. Slide 32: Economic Model

    VirtualScopics All Rights Reserved 32 Payers Payers see reduced cost through individual patients being on the right therapy Providers Providers receive more accurate information, allowing better treatment decisions. Patients Patients get on the right therapy sooner, enabling improved quality of life

  33. Slide 33: Quantitative Imaging Center - QIC

    VirtualScopics All Rights Reserved 33 Quantitative Imaging Center - QIC A centralized lab that receives medical images from global healthcare facilities and processes and delivers back quantitative assessments enabling improved patient outcomes at reduced cost. The center will be the first of its ki

  34. Slide 34: Current Focus

    VirtualScopics All Rights Reserved 34 • 510K Approval for DCE MRI blood flow measurement device • Revisions to the business model in light of delays in some of the key milestones resulting in not achieving the second Merck GHI investment • Developing a revised business plan Current Focus

  35. Slide 35: Outlook

    VirtualScopics All Rights Reserved 35 • We still believe Personalized Medicine can be a significant opportunity for the company • We will continue to provide updates during quarterly investor calls Outlook

  36. Slide 36: Financial Overview

    Financial Overview Molly Henderson Chief Business & Financial Officer, Sr. Vice President

  37. Slide 37: Revenues & Gross Profit – Yearly Trends

    VirtualScopics All Rights Reserved 37 Revenues & Gross Profit – Yearly Trends $1 $3 $5 $7 $9 $11 $13 $15 2007 2008 2009 2010 2011 2012 Millions Annual Revenues $- $1 $2 $3 $4 $5 $6 $7 $8 2007 2008 2009 2010 2011 2012 Millions Annual Gross Profit

  38. Slide 38: Revenue composition: 2009 - 2012

    VirtualScopics All Rights Reserved 38 Revenue composition: 2009 - 2012 - 2,000,000 4,000,000 6,000,000 8,000,000 10,000,000 12,000,000 14,000,000 16,000,000 2009 2010 2011 2012 Revenues by Clinical Trial Phase Phase III Phase II R&D/Phase I - 2,000,000 4,000,000 6,000,000 8,000,000 10,000,000 12,000

  39. Slide 39: Adjusted EBITDA – Yearly Trend

    VirtualScopics All Rights Reserved 39 Adjusted EBITDA* – Yearly Trend Demonstrated profitability of Core Lab operational model [2012 includes ~$.6M in Personalized Medicine investments] *Adjusted EBITDA = Earnings/Loss less Depreciation, Amortization, Interest, Stock Compensation Expense and Loss on

  40. Slide 40: 2nd Quarter/6 Month 2013 Results

    VirtualScopics All Rights Reserved 40 2 nd Quarter/6 Month 2013 Results 2013 2012 2013 2012 Revenues 3,706,677 3,335,861 6,239,264 7,038,019 Cost of services 1,936,594 1,991,924 3,683,889 4,283,169 Gross profit 1,770,083 1,343,937 2,555,375 2,754,850 Gross margin 48% 40% 41% 39% Operating expenses R

  41. Slide 41: Revenues & Gross Profit – Quarterly Trend

    VirtualScopics All Rights Reserved 41 Revenues & Gross Profit – Quarterly Trend $1,500,000 $2,000,000 $2,500,000 $3,000,000 $3,500,000 $4,000,000 Q1 2012 Q2 2012 Q3 2012 Q4 2012 Q1 2013 Q2 2013 Revenues $500,000 $700,000 $900,000 $1,100,000 $1,300,000 $1,500,000 $1,700,000 Q1 2012 Q2 2012 Q3 2012 Q4

  42. Slide 42: Adjusted EBITDA – Quarterly Trend

    VirtualScopics All Rights Reserved 42 Adjusted EBITDA* – Quarterly Trend Q2 2013 highest quarter of cash generation in the last 6 quarters *Adjusted EBITDA = Earnings/Loss less Depreciation, Amortization, Interest, Stock Compensation Expense and Loss on Derivative Q1 2013 Adjusted EBITDA loss associ

  43. Slide 43: June 30, 2013 Balance Sheet

    VirtualScopics All Rights Reserved 43 June 30, 2013 Balance Sheet June 30, December 31, 2013 2012 Assets (unaudited) Current assets Cash 7,145,743$ 8,523,807$ Accounts receivable, net 2,968,997 1,762,507 Prepaid expenses and other current assets 311,685 437,698 Total current assets 10,426,425 10,724

  44. Slide 44: 2013 Project Awards Composition - by Therapeutic Area

    VirtualScopics All Rights Reserved 44 2013 Project Awards Composition - by Therapeutic Area 0 2 4 6 8 10 12 14 $0 $1 $2 $3 $4 $5 $6 $7 $8 Millions Project Dollars # of Projects

  45. Slide 45: Capitalization

    VirtualScopics All Rights Reserved 45 Capitalization: NASDAQ: VSCP Common shares outstanding: 29.7MM Convertible preferred securities: 4.8MM Warrants/Options: 8.2MM NASDAQ 52 week range: $0.38 - $0.96 Market cap:~ $14MM Stockholder concentration (as of April 30, 2013): (Beneficial Ownership Percenta

  46. Slide 46: Company Mission

    VirtualScopics All Rights Reserved 46 Our mission is to improve the lives of those impacted by disease and disability Company Mission

  47. Slide 47: Stock Price

    Stock Price GF \* VIRTUALSCOPICS

  48. Slide 48: Shareholder Value

    VirtualScopics All Rights Reserved 48 • We recognize the depressed value of our stock price vs. historic levels • We believe the primary remedy for this is enhanced business performance – We think we have begun to demonstrate this • We are committed to proactively position the company to prospective

  49. Slide 49: Path Forward with NASDAQ

    Path Forward with NASDAQ GF VIRTUALSCOPICS

  50. Slide 50: Reverse Stock Split

    VirtualScopics All Rights Reserved 50 • Concurrent with the passing of the change in our certificate of incorporation to allow the board to authorize a reverse stock split we will proceed – unless daily trading signals we can achieve compliance through natural means • Action anticipates incorporatio

  51. Slide 51: CFO Recruitment

    VirtualScopics All Rights Reserved 51 • Initiating interviews with a short list of solid candidates • In the interim we have a solid plan to cover CFO responsibilities • Will get back to you shortly on our plan going forward CFO Recruitment

  52. Slide 52: Summary

    VirtualScopics All Rights Reserved 52 Summary Clinical Trial Business • 2 nd quarter was good financially • Good progress on new study awards year to date • Much more work required Personalized Medicine • Focus on 510K for DCE MRI application • Revising business plan • Can be a significant opportuni

  53. Slide 53: Thank You Question and Answer

    VirtualScopics All Rights Reserved 53 Thank You Question and Answer

  54. Slide 54: Thank You

    VirtualScopics All Rights Reserved 54 On behalf of the VirtualScopics’ Board of Directors and Employees Thank You

VirtualScopics — Shareholder Meeting (August 2013) on 6ix